

SUPPLEMENTARY TABLE S3. PREVALENCE OF ANTIBODY SEROREACTIVITY IN AIDS-NON-HODGKIN LYMPHOMA CASES AND CONTROLS

Antigen	AIDS-NHL								
	Controls (n=67)		All cases (n=66)		Incident (n=28)		Prevalent (n=38)		Incident vs. Prevalent p-Value*
	n	%	n	%	n	%	n	%	
<b>Human herpesviruses</b>									
HSV1 IgG	46	68.7	46	69.7	21	75.0	25	65.8	.42
HSV2 2mgG	41	61.2	29	43.9	12	42.9	17	44.7	.88
VZV gE	7	10.5	8	12.1	6	21.4	2	5.3	.06
VZV gI	7	10.5	5	7.6	2	7.0	3	7.9	1.00
EBV VCA p18	67	100.0	66	100.0	28	100.0	38	100.0	—
EBV Zebra	59	88.1	52	78.8	20	71.4	32	84.2	.21
EBV EA-D	54	80.6	50	75.8	19	67.9	31	81.6	.20
EBV EBNA1	54	80.6	55	83.3	27	96.4	28	73.7	<b>.02</b>
CMV pp 150	60	89.6	52	78.8	23	82.1	29	76.3	.57
CMV pp 28	60	89.6	61	92.4	26	92.9	35	92.1	1.00
CMV pp 52	67	100.0	65	98.5	28	100.0	37	97.4	1.00
HHV6 1E1A	7	10.5	12	18.2	4	14.3	8	21.1	.48
HHV6 1E1B	13	19.4	6	9.1	2	7.1	4	10.5	1.00
HHV7 U14	15	22.4	17	25.8	6	21.4	11	28.9	.49
HHV8 LANA	17	25.4	17	25.8	8	28.6	9	23.7	.65
HHV8 K8.1	9	13.4	11	16.7	6	21.4	5	13.2	.51
<b>Hepatitis virus</b>									
HBc	46	68.7	38	57.6	18	64.3	20	52.6	.34
HBe	40	59.7	36	54.6	17	60.7	19	50.0	.39
HCV1a NS3	10	14.9	5	7.6	4	14.3	1	2.6	.15
<b>Human T lymphotropic virus</b>									
HTLV1 gag	2	3.0	0	0.0	0	0.0	0	0.0	—
HTLV1 env	2	3.0	3	4.6	0	0.0	3	7.9	—
<b>Human polyomavirus</b>									
BKV	53	79.1	52	78.8	18	64.3	34	89.5	<b>.01</b>
JCV	18	26.9	9	13.6	4	14.3	5	13.2	1.00
KIV	5	67.2	39	59.1	18	64.3	21	55.3	.46
WUV	57	85.1	42	63.6	23	82.1	19	50.0	<b>.007</b>
MCV	43	64.2	36	54.6	15	53.6	21	55.3	.89
HPyV6	46	68.7	45	68.2	22	78.6	23	60.5	.12
HPyV7	24	35.8	26	39.4	10	35.7	16	42.1	.60
TSV	48	71.6	38	57.6	16	57.1	22	57.9	.95
HPyV9	5	7.5	8	12.2	2	7.1	6	15.8	.45
HPyV10	54	80.6	56	84.9	26	92.9	30	78.9	.17
LPV	2	3.0	3	4.6	0	0.0	3	7.9	.26

\*p-Values comparing incident vs. prevalent cases by chi-square test or Fisher's exact test. **Bold** font indicates p-value < .05. AIDS-NHL, AIDS-non-Hodgkin lymphoma.